2 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 2, Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Donor Lymphocyte Infusion: new trials by email Literature Review of Donor Lymphocyte Infusion trials Research Report on Donor Lymphocyte Infusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) Venetoclax, Azacitidine, Donor Lymphocyte Infusion - Acute Myeloid Leukemia | Phase 1 | Terminated | Antonio M Jimenez Jimenez | 2 | 2024-12-04 | 2026-07-13 |
| Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies donor lymphocyte infusion, Cyclophosphamide, Busulfan - Hematologic Neoplasms | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 430 | 2022-05-23 | 2026-10-16 |
| Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Anti-thymocyte globulin (rabbit), Busulfan, Fludarabine - Severe Combined Immunodeficiency | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 4 | 2021-09-02 | 2026-09-16 |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis - Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 1 / Phase 2 | Terminated | Sumithira Vasu | 4 | 2020-01-10 | 2025-05-21 |
| Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation donor lymphocyte infusion - Hematological Malignancy | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 11 | 2010-02-01 | 2013-01-14 |
| Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion donor lymphocyte infusion - Hematologic Neoplasms, Relapse | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 21 | 2005-12-01 | 2011-01-24 |
Hematologic Neoplasms (3) · Leukemia, Myeloid, Acute (2) · Recurrence (2) · Bronchiolitis Obliterans Syndrome (1) · Graft vs Host Disease (1) · Neoplasm, Residual (1) · Severe Combined Immunodeficiency (1)
Assistance Publique - Hôpitaux de Paris (2) · Antonio M Jimenez Jimenez (1) · National Cancer Institute (NCI) (1) · St. Jude Children's Research Hospital (1) · Sumithira Vasu (1)
United States (4) · France (2)
Antonio M Jimenez Jimenez, MD (1) · Christopher G Kanakry, M.D. (1) · Ewelina Mamcarz, MD (1) · Sumithira Vasu, MBBS (1)